- Home
- Publications
- Publication Search
- Publication Details
Title
Buparlisib is a brain penetrable pan-PI3K inhibitor
Authors
Keywords
-
Journal
Scientific Reports
Volume 8, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-07-11
DOI
10.1038/s41598-018-29062-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial
- (2017) Denis Soulières et al. LANCET ONCOLOGY
- Is the blood–brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data
- (2017) Jann N Sarkaria et al. NEURO-ONCOLOGY
- Regulation of T cell alloimmunity by PI3Kγ and PI3Kδ
- (2017) Mayuko Uehara et al. Nature Communications
- Blood-brain-barrier spheroids as an in vitro screening platform for brain-penetrating agents
- (2017) Choi-Fong Cho et al. Nature Communications
- PI3K–mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models
- (2016) Fan Lin et al. CLINICAL CANCER RESEARCH
- PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo
- (2016) H. Niessner et al. CLINICAL CANCER RESEARCH
- Impact of Blood-Brain Barrier Integrity on Tumor Growth and Therapy Response in Brain Metastases
- (2016) M. Osswald et al. CLINICAL CANCER RESEARCH
- PI3Kγ is a molecular switch that controls immune suppression
- (2016) Megan M. Kaneda et al. NATURE
- Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases
- (2016) Jing Ni et al. NATURE MEDICINE
- The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas
- (2016) D. F. Quail et al. SCIENCE
- Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR
- (2016) Timothy P. Heffron et al. ACS Medicinal Chemistry Letters
- BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma
- (2016) Maria-Carmela Speranza et al. Scientific Reports
- FDA Approval: Idelalisib Monotherapy for the Treatment of Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma
- (2015) B. W. Miller et al. CLINICAL CANCER RESEARCH
- Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
- (2015) O. van Tellingen et al. DRUG RESISTANCE UPDATES
- ABCB1 and ABCG2 restrict the brain penetration of a panel of novel EZH2-Inhibitors
- (2015) Ping Zhang et al. INTERNATIONAL JOURNAL OF CANCER
- A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors
- (2014) R. El Meskini et al. Disease Models & Mechanisms
- PI3K and cancer: lessons, challenges and opportunities
- (2014) David A. Fruman et al. NATURE REVIEWS DRUG DISCOVERY
- The Somatic Genomic Landscape of Glioblastoma
- (2013) Cameron W. Brennan et al. CELL
- Targeting the PI3K Pathway in the Brain--Efficacy of a PI3K Inhibitor Optimized to Cross the Blood-Brain Barrier
- (2012) L. Salphati et al. CLINICAL CANCER RESEARCH
- Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations
- (2012) S. M. Brachmann et al. MOLECULAR CANCER THERAPEUTICS
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Antitumor Activity of NVP-BKM120--A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma Cells
- (2011) D. Koul et al. CLINICAL CANCER RESEARCH
- Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors
- (2011) Paola Di Gion et al. CLINICAL PHARMACOKINETICS
- In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein
- (2011) Chunbo Zhang et al. EPILEPSIA
- Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
- (2011) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
- (2011) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer
- (2011) Matthew T. Burger et al. ACS Medicinal Chemistry Letters
- PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel
- (2010) Yong Zhang et al. COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE
- Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in Medulloblastoma
- (2010) S. Buonamici et al. Science Translational Medicine
- Several major antiepileptic drugs are substrates for human P-glycoprotein
- (2008) Carlos Luna-Tortós et al. NEUROPHARMACOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started